Age-related common miRNA polymorphism associated with severe toxicity in lung cancer patients treated with platinum-based chemotherapy

被引:18
|
作者
Fang, Chao [1 ,2 ]
Li, Xiang-Ping [3 ]
Gong, Wei-Jing [1 ,2 ]
Wu, Na-Yiyuan [1 ,2 ]
Tang, Jie [1 ,2 ]
Yin, Ji-Ye [1 ,2 ]
Li, Xi [1 ,2 ]
Zhang, Wei [1 ,2 ]
Zhou, Hong-Hao [1 ,2 ,4 ]
Liu, Zhao-Qian [1 ,2 ,4 ]
机构
[1] Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Hunan, Peoples R China
[2] Cent S Univ, Hunan Key Lab Pharmacogenet, Inst Clin Pharmacol, Changsha, Hunan, Peoples R China
[3] Cent S Univ, Dept Pharm, Xiangya Hosp, Changsha, Hunan, Peoples R China
[4] Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang, Peoples R China
基金
中国国家自然科学基金;
关键词
lung cancer; miRNA; platinum-based chemotherapy; polymorphism; toxicity; FUNCTIONAL POLYMORPHISM; HIGH-RISK; MICRORNAS; SUSCEPTIBILITY; BIOMARKERS; MIR-146A; EXPRESSION; SURVIVAL; MIR-27; GENES;
D O I
10.1111/1440-1681.12704
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Platinum-based chemotherapy toxicity severely impedes successful treatment in lung cancer patients. MicroRNAs (miRs) have a significant impact on the occurrence and survival rate of lung cancer. The purpose of this study was to investigate the association between common miRNA variants and platinum-based chemotherapy toxicity in lung cancer patients. A total of eight functional single nucleotide polymorphisms (SNPs) of miRNA were genotyped in 408 lung cancer patients by MALDI-TOF mass spectrometry. All the patients were histologically confirmed as lung cancer, and were treated with platinum-based chemotherapy for at least two cycles. It was found that the polymorphism rs2042553 of miR-5197 had a significant association with overall severe toxicity in both additive (P=.031, odds ratio [OR]=1.41, 95% confidence interval [CI] 1.03-1.93) and dominant (P=.009, OR=1.80, 95% CI 1.16-2.80) models. MiR-605 rs2043556 was significantly related to severe hepatotoxicity in dominant model (P=.022, OR=2.51, 95% CI 1.12-4.14). In addition, rs2910164 of miR-146a had marginal statistical effect on severe hepatotoxicity in additive model (P=.054). The subgroup analyses showed that miR-27a rs895819 was related to gastrointestinal toxicity in age >56years old, smoking and non-smoking patients. Taken together, our results revealed that polymorphisms of miR-5197, miR-605, miR-146a, and miR-27a contributed to the chemotherapy toxicity of lung cancer, which may serve as a predictive tool for toxicity evaluation of platinum-based chemotherapy in lung cancer patients.
引用
收藏
页码:21 / 29
页数:9
相关论文
共 50 条
  • [1] XPF polymorphism toward lung cancer susceptibility and survival in patients treated with platinum-based chemotherapy
    Lawania, Shweta
    Sharma, Siddharth
    Singh, Navneet
    Behera, Digamber
    FUTURE ONCOLOGY, 2018, 14 (11) : 1071 - 1089
  • [2] Association of variations in the CAT and prognosis in lung cancer patients with platinum-based chemotherapy
    Liu, Jia-Si
    Liu, Jun-Yan
    Xiao, Qi
    Li, Xiang-Ping
    Chen, Juan
    Liu, Zhao-Qian
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [3] Functional miRNA variants affect lung cancer susceptibility and platinum-based chemotherapy response
    Fang, Chao
    Li, Xiang-Ping
    Chen, Yi-Xin
    Wu, Na-Yiyuan
    Yin, Ji-Ye
    Zhang, Wei
    Zhou, Hong-Hao
    Liu, Zhao-Qian
    JOURNAL OF THORACIC DISEASE, 2018, 10 (06) : 3329 - 3340
  • [4] Erythropoietin promoter polymorphism is associated with treatment efficacy and severe hematologic toxicity for platinum-based chemotherapy
    Zheng, Yi
    Deng, Zheng
    Tang, Mimi
    Cai, Pei
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (04) : 495 - 502
  • [5] Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy
    Puskas, Rita
    Bikov, Andras
    Horvath, Peter
    Lazar, Zsofia
    Kunos, Laszlo
    Nagy, Reka
    Pinter, Gabriella
    Galffy, Gabriella
    PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27
  • [6] Rho GTPases: RAC1 polymorphisms affected platinum-based chemotherapy toxicity in lung cancer patients
    Zou, Ting
    Yin, Jiye
    Zheng, Wei
    Xiao, Ling
    Tan, Liming
    Chen, Juan
    Wang, Ying
    Li, Xiangping
    Qian, Chenyue
    Cui, Jiajia
    Zhang, Wei
    Zhou, Honghao
    Liu, Zhaoqian
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 249 - 258
  • [7] WISP1 Polymorphisms Contribute to Platinum-Based Chemotherapy Toxicity in Lung Cancer Patients
    Chen, Juan
    Yin, Jiye
    Li, Xiangping
    Wang, Ying
    Zheng, Yi
    Qian, Chenyue
    Xiao, Ling
    Zou, Ting
    Wang, Zhan
    Liu, Junyan
    Zhang, Wei
    Zhou, Honghao
    Liu, Zhaoqian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (11): : 21011 - 21027
  • [8] Association between well-characterized lung cancer lncRNA polymorphisms and platinum-based chemotherapy toxicity in Chinese patients with lung cancer
    Gong, Wei-jing
    Peng, Jing-bo
    Yin, Ji-ye
    Li, Xiang-ping
    Zheng, Wei
    Xiao, Ling
    Tan, Li-ming
    Xiao, Di
    Chen, Yi-xin
    Li, Xi
    Zhou, Hong-hao
    Liu, Zhao-qian
    ACTA PHARMACOLOGICA SINICA, 2017, 38 (04) : 581 - 590
  • [9] Hsa-miR-196a2 Functional SNP is Associated With Severe Toxicity After Platinum-Based Chemotherapy of Advanced Nonsmall Cell Lung Cancer Patients in a Chinese Population
    Zhan, Xiaoying
    Wu, Wenting
    Han, Baohui
    Gao, Ge
    Qiao, Rong
    Lv, Juan
    Zhang, Shuyu
    Zhang, Wei
    Fan, Weiwei
    Chen, Hongyan
    Zhang, Tianbao
    Gu, Aiqin
    Shen, Jie
    Wu, Qihan
    Lu, Daru
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2012, 26 (06) : 441 - 446
  • [10] A miR-15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum-based chemotherapy
    Xue, Ping
    Zhang, Guopei
    Zhang, Hongchao
    Cui, Su
    Zhang, Liang
    Yu, Tao
    Xiao, Mingyang
    Li, Liuli
    Lu, Xiaobo
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022, 26 (21) : 5439 - 5451